| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/01/2002 | WO2002058450A2 Regulation of cell growth by muc1 |
| 08/01/2002 | WO2002045749A3 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 08/01/2002 | WO2002042278A3 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 08/01/2002 | WO2002032410A3 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders |
| 08/01/2002 | WO2002030461A3 Methods for treating disorders of the female reproductive system |
| 08/01/2002 | WO2002030441A3 Treatment of cancers by aplidine in conjunction with a myoprotector |
| 08/01/2002 | WO2002022166A3 Tweak receptor agonists as anti-angiogenic agents |
| 08/01/2002 | WO2002017963A3 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction |
| 08/01/2002 | WO2002012190A3 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 08/01/2002 | WO2002011766A3 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation |
| 08/01/2002 | WO2002008285A3 Il-17 molecules and uses thereof |
| 08/01/2002 | WO2002002625A3 Novel fibroblast growth factors and nucleic acids encoding same |
| 08/01/2002 | WO2001082914A3 Topical anesthetic/opioid formulations and uses thereof |
| 08/01/2002 | WO2001081325A3 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
| 08/01/2002 | WO2001080633A3 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 08/01/2002 | WO2001078697A3 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
| 08/01/2002 | WO2001072836A3 G-protein coupled receptors |
| 08/01/2002 | WO2001070955A3 Identification of essential genes in prokaryotes |
| 08/01/2002 | WO2001070738A3 Tri-aryl-substituted-ethane pde4 inhibitors |
| 08/01/2002 | WO2001064202A3 Tramadol for the treatment of functional gastrointestinal disorders |
| 08/01/2002 | WO2001062290A3 Methods and compositions for improving sleep |
| 08/01/2002 | WO2001032232A3 Method of forming micropores in skin |
| 08/01/2002 | WO2001026678A9 Short segments of dap-kinase |
| 08/01/2002 | WO2001022970A9 Therapy with 2-5a and interferon |
| 08/01/2002 | WO2000077040A9 Human intracellular signaling molecules |
| 08/01/2002 | US20020104113 Nav2 channel gene-deficient non-human animals |
| 08/01/2002 | US20020103340 Rab proteins |
| 08/01/2002 | US20020103337 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 08/01/2002 | US20020103251 Cholesterol-lowering therapy |
| 08/01/2002 | US20020103249 Combination of a serotonin reuptake inhibitor and irindalone |
| 08/01/2002 | US20020103242 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 08/01/2002 | US20020103239 Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity |
| 08/01/2002 | US20020103228 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications |
| 08/01/2002 | US20020103225 Comprises solid amorphous dispersion of compounds such as (2R,4S)4-((3,5-dichloro-benzyl)-methoxycarbonyl-amino)-6,7-dimethoxy-2 -methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester for elevating plasma lipid levels |
| 08/01/2002 | US20020103221 Such as 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo -(4,3-c)pyridin-5-yl)-1-(R)-benzyloxymethyl- 2-oxo-ethyl)-isobutyramide or prodrug thereof; for improving functional health of elderly/isolated |
| 08/01/2002 | US20020103164 Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
| 08/01/2002 | US20020103159 Chitosan and a polysaccharide selected from heparin, heparan sulphate manufacture lactating animals, particularly cows; prophylactic or wound healing treatment for mastitis; bacterial barrier; bacteriostats |
| 08/01/2002 | US20020103158 Dinucleoside polyphosphates which facilitate secretory mechanisms, i.e. increasing the hydration of mucus secretions, stimulating the production of mucins and increasing ciliary beat frequency to facilitate clearance |
| 08/01/2002 | US20020103157 Stimulation of tear secretion by administering uridine 5'-triphosphate dinucleotides, cytidine 5'-triphosphate, adenosine 5'-triphosphate or their useful analogs; enhances mucociliary clearance of nasolacrimal duct |
| 08/01/2002 | US20020103141 DNA topoisomerase I and cyclooxygenase-2 (COX-2) inhibiting agents |
| 08/01/2002 | US20020103139 Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control |
| 08/01/2002 | US20020103131 Prevention of diabetes by administration of GnRH antagonists |
| 08/01/2002 | US20020103127 Inhibitors of proteasomal activity for stimulating hair growth |
| 08/01/2002 | US20020103123 Administering coumpounds such as aromatic alkyl diamine derivatives as Y5 receptor agonist or antagonist to increase or decrease food consumption |
| 08/01/2002 | US20020103115 Useful in the development of human therapeutics and diagnostic compositions and methods |
| 08/01/2002 | US20020103112 Wound healing and treatment of fibrosis |
| 08/01/2002 | US20020103109 Methods and compositions for treating addiction disorders |
| 08/01/2002 | US20020102711 Polypeptide for use in the treatment of cancer and immunological |
| 08/01/2002 | US20020102710 Polypeptide for use in the treatment of cancer, autoimmune diseases and inflammation |
| 08/01/2002 | US20020102707 Nucleotide sequences coding polypeptide for use in the treatment of sexual disorders |
| 08/01/2002 | US20020102684 Human phospholipase inhibitor |
| 08/01/2002 | US20020102676 Nucleotide sequences coding membrane proteins for use in cancer therapy |
| 08/01/2002 | US20020102658 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof |
| 08/01/2002 | US20020102657 Binding protein for use as therapeutic tool in the prevention of Infections disease |
| 08/01/2002 | US20020102651 Novel B7-4 molecules and uses therefor |
| 08/01/2002 | US20020102649 Human transport protein homologs |
| 08/01/2002 | US20020102609 Antagonists of HMG1 for treating inflammatory conditions |
| 08/01/2002 | US20020102603 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 08/01/2002 | US20020102585 Prostate growth-associated membrane proteins |
| 08/01/2002 | US20020102566 Identification of neural defects associated with the nucleosomal assembly protein 112 gene |
| 08/01/2002 | US20020102552 Nucleotide sequences coding preferential polypeptide for use in the treatment of diabetes and eating disorders |
| 08/01/2002 | US20020102540 Functional dna clone for hepatitis c virus (hcv) and uses thereof |
| 08/01/2002 | US20020102316 Useful for treating snoring |
| 08/01/2002 | US20020102313 Composition for the relief of heat stress |
| 08/01/2002 | US20020102299 Triglyceride reducing agent |
| 08/01/2002 | US20020102298 Temperature-sensitive liposomal formulation |
| 08/01/2002 | US20020102296 Small particle liposome aerosols for delivery of anti-cancer drugs |
| 08/01/2002 | US20020102294 Aerosols comprising nanoparticle drugs |
| 08/01/2002 | US20020102292 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure |
| 08/01/2002 | US20020102279 Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties |
| 08/01/2002 | US20020102269 Contacting a parental Helicobacter with molecule in biological sample, testing and comparing response to extracellular pH and sensitivity to acidity of parental strain to a strain deficient in UreI; selecting molecule |
| 08/01/2002 | US20020102265 For diagnosis and imaging of cancer and tumor tissues |
| 08/01/2002 | US20020102263 Diagnosis and treatment of malignant neoplasms |
| 08/01/2002 | US20020102237 Compositions and methods for hepatitis treatment |
| 08/01/2002 | US20020102235 Novel imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus |
| 08/01/2002 | US20020100854 Furnace mount and method of installation |
| 08/01/2002 | DE10103454A1 Wirkstoffkonzentrate sowie Verfahren zu ihrer Herstellung Concentrates of active substance and process for their preparation |
| 08/01/2002 | DE10102977A1 Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose Test system for the development of therapeutics, in particular of drugs used to treat osteoporosis |
| 08/01/2002 | DE10100911A1 Verfahren zur Hormonersatztherapie und dessen Darreichungsform A method for hormone replacement therapy and its dosage form |
| 08/01/2002 | CA2563051A1 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | CA2436139A1 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | CA2436091A1 Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
| 08/01/2002 | CA2435888A1 Method of preparing biological materials and preparation produced using same |
| 08/01/2002 | CA2435829A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | CA2435781A1 Method for detecting of prions in a sample |
| 08/01/2002 | CA2435562A1 Carotenoids as anti-hypertension agents |
| 08/01/2002 | CA2435510A1 Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2.alpha.alphaactivity and methods of treating cancer |
| 08/01/2002 | CA2435418A1 Use of neurotoxic substances in producing a medicament for treating joint pains |
| 08/01/2002 | CA2435047A1 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | CA2434765A1 Degradation-resistant glucocorticosteroid formulations |
| 08/01/2002 | CA2434504A1 Combinations of sterol absorption inhibitor(s) with blood modifiers for treating vascular conditions |
| 08/01/2002 | CA2434488A1 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | CA2434436A1 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 08/01/2002 | CA2434430A1 The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| 08/01/2002 | CA2434320A1 Chemokines as adjuvants of immune response |
| 08/01/2002 | CA2434052A1 Use of rhein for preparing a medicine for treating a high level of il-1 |
| 08/01/2002 | CA2434033A1 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | CA2433762A1 Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy |
| 08/01/2002 | CA2433681A1 Sulfatases and methods of use thereof |
| 08/01/2002 | CA2432991A1 Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |